| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -103,941 | -71,691 |
| Depreciation and amortization | 9,838 | 6,611 |
| Stock-based compensation | 19,396 | 14,535 |
| Accretion and amortization of premiums and discounts on investments, net | 2,725 | 1,915 |
| Deferred revenue | -389 | -393 |
| Change in fair value of stock price appreciation milestones | -117 | -207 |
| (gain) loss on disposal of property and equipment | 36 | 36 |
| Accounts receivable | -2,857 | -2,144 |
| Prepaid expenses and other assets | -4,165 | -3,139 |
| Accounts payable and accrued expenses | -9,892 | -9,342 |
| Right-of-use assets and lease liabilities, net | -1,926 | -1,241 |
| Net cash used in operating activities | -82,770 | -58,396 |
| Proceeds from sale of property and equipment | 125 | 122 |
| Purchases of property and equipment | 4,761 | 2,558 |
| Purchases of investments | 157,412 | 99,437 |
| Maturities of investments | 245,584 | 164,137 |
| Net cash provided by (used in) investing activities | 83,536 | 62,264 |
| Issuance of common stock from equity incentive plans, net of issuance costs | 0 | 0 |
| Proceeds from public offering of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 | 0 |
| Proceeds from ft819 cirm award | 0 | 0 |
| Proceeds from ft836 cirm award | -3,800 | -1,325 |
| Net cash provided by financing activities | 3,800 | 1,325 |
| Net change in cash, cash equivalents and restricted cash | 4,566 | 5,193 |
| Cash and cash equivalents at beginning of period | 46,283 | - |
| Cash and cash equivalents at end of period | 50,849 | - |
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)